FDA, vaccine and covid shots
Digest more
Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development strategy,
A spokesman for Moderna, which makes Covid vaccines, pointed to a September statement saying the company didn’t know of any new safety concerns, including deaths, related to its product. Pfizer and Novavax, which also make Covid vaccines for the U.S., didn’t respond to requests for comment.
A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights ...
If you have ever wondered whether Novavax is undervalued, overhyped, or a hidden gem in the biotech space, you are definitely not alone. The stock recently ticked up 1.8% over the past week, but has struggled in the bigger picture,
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed to working to ensure that anyone eligible who wants a ...
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. Additional analyses of the ...
Zacks Investment Research on MSN
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this vaccine maker have returned -23.
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from a direct COVID-19 commercial operation to an R&D-focused company,